Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of “Hold” by Analysts

Sutro Biopharma, Inc. (NASDAQ:STRO) has been given a consensus recommendation of “Hold” by the eight analysts that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $33.60.

Several equities research analysts recently weighed in on the company. HC Wainwright lifted their price objective on Sutro Biopharma to $10.00 and gave the stock a “neutral” rating in a report on Monday, December 22nd. Wedbush reiterated a “neutral” rating and issued a $100.00 target price (up previously from $20.00) on shares of Sutro Biopharma in a research note on Tuesday, December 2nd. Wall Street Zen lowered shares of Sutro Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sutro Biopharma in a report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Sutro Biopharma in a report on Monday, December 22nd.

Insider Buying and Selling at Sutro Biopharma

In related news, Director Connie Matsui acquired 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The shares were bought at an average cost of $8.00 per share, for a total transaction of $40,000.00. Following the purchase, the director owned 5,000 shares in the company, valued at $40,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders acquired 11,175 shares of company stock valued at $89,598 in the last three months. 3.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Jacobs Levy Equity Management Inc. bought a new stake in shares of Sutro Biopharma during the third quarter valued at about $387,000. Velan Capital Investment Management LP grew its stake in Sutro Biopharma by 2.0% during the third quarter. Velan Capital Investment Management LP now owns 3,120,000 shares of the company’s stock valued at $2,709,000 after acquiring an additional 60,000 shares in the last quarter. Bank of America Corp DE grew its stake in Sutro Biopharma by 51.3% during the third quarter. Bank of America Corp DE now owns 119,434 shares of the company’s stock valued at $104,000 after acquiring an additional 40,488 shares in the last quarter. Shay Capital LLC increased its holdings in Sutro Biopharma by 20.1% during the 3rd quarter. Shay Capital LLC now owns 312,051 shares of the company’s stock worth $271,000 after acquiring an additional 52,162 shares during the period. Finally, Two Sigma Investments LP lifted its stake in Sutro Biopharma by 244.8% in the 3rd quarter. Two Sigma Investments LP now owns 396,785 shares of the company’s stock worth $345,000 after purchasing an additional 281,717 shares in the last quarter. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Trading Down 0.9%

Sutro Biopharma stock opened at $11.57 on Friday. The business’s 50 day simple moving average is $9.60 and its 200 day simple moving average is $8.93. Sutro Biopharma has a 12 month low of $5.23 and a 12 month high of $21.50. The company has a market cap of $98.46 million, a price-to-earnings ratio of -0.44 and a beta of 1.52.

Sutro Biopharma (NASDAQ:STRO) last issued its earnings results on Thursday, November 6th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.25). Sutro Biopharma had a negative net margin of 206.77% and a negative return on equity of 852.70%. The firm had revenue of $9.69 million during the quarter, compared to the consensus estimate of $10.14 million. As a group, equities research analysts forecast that Sutro Biopharma will post -2.92 earnings per share for the current fiscal year.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.